Effectiveness of vaccination in preventing severe SARS CoV-2 infection in South India-a hospital-based cross-sectional study

Charles Pon Ruban A[1], Aazmi M[1], K.Shantaraman[2]*

[1] Department of Community Medicine, Tirunelveli Medical College, Tamil Nadu,India

[2] Department of Pathology, Tirunelveli Medical College, Tamil Nadu, India

*Corresponding author: K.Shantaraman; email: shantaraman_kal@tvmc.ac.in

Professor of Pathology,

Tirunelveli Medical College

Tirunelveli -11,Tamil Nadu,India

Abstract:

Background & objectives:

Establishing concrete evidence on effect of vaccination on severity of SARS CoV-2 infections in real world situations is the need of the hour. The aim of this study is to estimate the effectiveness Covid 19 vaccines in preventing the new and severe SARS CoV-2 infections.

Methods: We did this retrospective cross-sectional study among the 4765 patients consecutive adult inpatients admitted in the Covid 19 wards of a tertiary care hospital from May 1,2021 to July 7, 2021 during the second wave of Covid 19 pandemic. Information on basic demographic variables, RT PCR status, vaccination status, outcome and clinical severity of illness were obtained from the electronic hospital patient records.

Results, and Interpretation & conclusions:

Type of vaccine and number of doses of vaccines didn't have any protective effect against new SARS CoV-2 infection. Covid 19 patients vaccinated with at least one dose had 75 % less risk of requiring oxygen (OR 0.25 CI: 0.15 to 0.44) and 60 % less risk of ICU admission (OR 0.4 CI: 0.2 to 0.6) and it was statistically significant. Only 31 % of fully vaccinated Covid 19 positive patients had oxygen requirement (90% less risk) and 15% of the fully vaccinated patients had needed ICU admission (90% less risk).

Conclusion:

Vaccination didn't protect against SARS Cov-2 infection however significant protection was documented against severe SARS Cov-2 infection. Vaccination coverage should be increased urgently in order to halt the impending wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Keywords: Covid vaccine, Effectiveness of Covid vaccine, SARS CoV-2, Severe covid 19

Introduction:

Damage caused by the Novel SARS-CoV-2 virus on global health is indescribable (1). As of August 9th of 2021, globally 20,22,96,216 people were affected and 42,88,134 deaths were caused by SARS CoV-2(2). Vaccination drive is one of the most imperative strategies ratified to combat the deadly pandemic. Eradication of the Covid19 may be too aspirational a goal given the current situation; elimination of Covid 19 is still a realistic goal. Israel has achieved an all-time low level of infections of SARS-CoV-2 with high vaccination coverage(3). India being the pharmaceutical hub; there are 8 vaccines in the pipeline under various phases of the clinical trial, 2 vaccines – Covishield and Covaxin were approved for restricted emergency use by the Drugs Controller General of India (DCGI)(4). Covishield, produced by Serum Institute of India in synergy with Oxford University and Pharmaceutical giant Astra Zeneca uses a non-replicating adenovirus viral vector that infects chimpanzees given in 2 doses 84 days apart. The efficacy of the vaccine was found to be 76% after the first dose. If the interval between the first and second dose was extended to 12 weeks or more the efficacy rose to 91.6%(5). Covaxin, a domestic vaccine developed in the country by Bharat Biotech in collaboration with the Indian Institute of Medical Research (ICMR) and subsidiary National Institute of Virology (assisted by isolating virus sample) is an inactivated vaccine given 28 days apart with a vaccine efficacy of 81%(6).

The national covid vaccination program was launched on 16 January 2021 in the country with the first phase covering Health Care workers and frontline workers. Considering high mortality in elderly and comorbid people, vaccination for greater than 60 years and with Comorbid diseases in 45-60 years age group was started from 1 March 2021. Further on all people in the age group of 45-60 years irrespective of the comorbid status were included in the vaccination drive from 1 April 2021. Vaccination for 18-44 years was kicked off from 1 May 2021(7).

Vaccine efficacy is defined as reduced risk of infection or disease among vaccinated individuals resulting from vaccination in carefully controlled circumstances; estimated from randomized clinical trials.

Vaccine effectiveness is reduced risk of infection or disease among vaccinated individuals attributed to vaccination in real-world conditions; estimated from observational (non-randomized) studies. Gauging COVID-19 vaccine performance in the real world is crucial. Several factors like cold chain management during transportation and storage, completing dosing schedule, the inclusion of the general population (as people enrolled in a clinical trial are many times young and healthy) has a bearing on real-world vaccine effectiveness(8). Vaccine hesitancy is one of the top ten global health threats reported by the World health organization which threatens the progress made against vaccine-preventable diseases(9). In Tamil Nadu, only 5.9% of the people were fully vaccinated and 26% of the people had received at least one dose of vaccination which is below the national average (8.1% and 28.6% respectively)(10). With high vaccine hesitancy among the population, providing concrete evidence on the effect of vaccination on the severity of the disease has become crucial and need of the hour. Hence this study was mapped out to analyse vaccine effectiveness in preventing severe SARS CoV-2 infection as there is a significant dearth of such studies in our country to arrive at a decisive policy on vaccination.

Objective:

1. To estimate the proportion of patients with severe SARS CoV-2 infections among the Severe Acute Respiratory illness infection (SARI) patients admitted in Covid 19 wards in a tertiary care hospital, South India

2. To estimate the occurrence of new SARS CoV-2 infections following Covid vaccination among the patients admitted in Covid 19 wards in a tertiary care hospital, South India.

3. To find out the effectiveness of Covid vaccination in preventing the severe SARS CoV-2 infections among the patients admitted in Covid 19 wards in a tertiary care hospital, South India

Methodology:

Study setting: Triage Centre and Covid 19 ward of a tertiary care hospital, South India

Study design: Retrospective Cross-sectional study

Study period: May 7, 2021, to July 7, 2021

Study population: Inpatients admitted in Covid 19 wards

Inclusion criteria: All adult patients (Aged ≥ 13 years) admitted in Covid 19 wards during the above said period were included.

Exclusion criteria:

Antenatal mothers and children (aged <13 years) were excluded from the study population as vaccination for them wasn't started yet.

Patients with incomplete data on outcome measured were excluded from the study.

Sampling method: Consecutive sampling

Study procedure:

We did this retrospective cross-sectional study among the consecutive adult inpatients admitted in the Covid 19 wards of a tertiary care hospital, South India in the above said period. Our hospital is a government-run medical college hospital. It offers speciality and super speciality and allied health services and caters also to the neighbouring districts. All the patients admitted are tested for SARS-COV2 infection via nasopharyngeal and oropharyngeal swabs and the samples are transported to the designated Microbiological Lab within the College campus and the turnover time for report generation is within 12 hours.

An Electronic patient record database (Google sheet) has been developed and maintained by the hospital Covid control room and the required study variables were extracted from the database. After getting approval from the Institutional ethics committee, the following variables were collected; Name, age, sex, phone number, address, district, presence of symptoms, history of comorbid conditions, RT PCR status, SPO2, Respiratory rate, outcome, vaccination status, type of vaccine taken, number of doses, date of first positive and the difference between the date of RT PCR positive and date of vaccination. Self-reporting of vaccination status was confirmed through verification in the COWIN portal. The clinical severity of illness was categorized based upon the Respiratory Rate and Spo2 level measured at the time of admission.

Clinical guidelines for the management of Covid 19 issued by the Ministry of Health and family welfare, Government of India was followed for disease classification as follows:(11).

Mild: SpO2 >94 and RR<24/min; *Moderate*: SpO2 90 - 94 and RR 24 - 30 /min

Severe: SpO2 < 90 and RR >30 /min.

World health organization definition for SARI (severe acute respiratory illness infection) was used. SARI is defined as a hospitalized person with an acute respiratory infection, with a history of fever or measured fever of ≥ 38°C and cough with onset within the last 10 days(8).

Vaccine breakthrough infection is defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after they have completed all recommended doses of COVID-19 vaccine(12).

Outcomes:

The proportion of patients with severe Covid 19 (patients require oxygen; patients requiring ICU admission, the proportion of patients died).

Incidence of Covid 19 infection following vaccination

The proportion of patients with severe Covid 19 (patients requiring oxygen; patients requiring ICU admission, the proportion of patients died) following vaccination

Data analysis:

Data entry was done with Microsoft Excel and data analysis was done with SPSS 23 Version. Frequencies and proportions were calculated as appropriate. Means, Range and standard deviation were calculated for quantitative variables. The difference between the proportions was calculated using the Chi-Square test. Differences between more than two proportions were calculated using the Chi-Square trends.

Results:

A total of 4765 patients have been admitted in Covid 19 wards during the above said period. After excluding the antenatal mothers and children (353) and patients with incomplete data about the outcome studied (734), a total of 3679 patients were included in this study. The majority of the patients were male (60%). The majority of the patients belonged to the age group of 61-70 years (27.2%) followed by the 51-60 years (26.2%) age group. The mean age of the study population was 56.8 years and the standard deviation was 14.2. (Table 1)

95% of the patients were symptomatic and 53 % of the patients had co-morbid conditions. Among the patients presented with SARI (Severe acute respiratory illness), 44% were RT-PCR positive. Among the SARI cases, 65% of the patients needed ICU care on admission. The proportion of SARI patients admitted post-Covid vaccination was 3.7%. The proportion of patients with SARI who needed oxygen was 80.6% and the Proportion of patients with SARI who needed ICU admission was 65%. The proportion of patients who died during the hospital stay was 23.4%. The proportion of patients with RT-PCR positive needed oxygen was 78.5% and the Proportion of patients with RT-PCR positive needed ICU admission was 63%. The proportion of patients who died during the hospital stay was 29.5% (Table 1).

New COVID 19 infection following vaccination:

Our study didn't find any protective effect of vaccination against new COVID 19 infections. Type of vaccine nor number of doses has any effect on new infection. Those who had prior vaccination have 1.2 times more odds of becoming positive with RT PCR when compared to patients who didn't have vaccination; however, it is not statistically significant($p>0.05$). More samples are needed to conclude further. Out of the 21 patients who had more than 2 doses of vaccines, the data on days between the second dose of vaccination and date of RT PCR positive was available for 16 patients. 7 of them (43.8%) had a breakthrough infection (RT PCR positive after 14 days of vaccination). (Table 3)

The proportion of patients who needed oxygen:

Those aged more than 59 years (1.7 times) and patients without co-morbidity (1.5 times) have higher odds of requiring oxygen therapy and it was statistically significant($p<0.05$). There was no significant difference exists between the two groups in terms of sex and residence. (Table 2)

SARI patients with at least one dose of Covid 19 vaccine and fully vaccinated SARI patients had a 62% and 80% reduction in the need for oxygen therapy respectively when compared to patients without vaccination. both of them were statistically significant($p<0.05$). RTPCR positive patients with at least one dose of Covid 19 vaccine and full vaccinated RTPCR positive patients had 75% and 90% reduction in the need for oxygen therapy respectively when compared to patients with RT PCR negative and it was statistically significant ($p<0.05$). Both were statistically significant($p<0.05$). (Table 4)

The proportion of patients who needed ICU admission:

Females (1.2 times), those aged more than 59 years (1.5 times) and patients without co-morbidity (1.4 times) have higher odds of needing ICU care on admission and it was statistically significant($p<0.05$). (Table 2)

SARI patients with at least one dose of Covid 19 vaccine and fully vaccinated SARI patients had a 50% and 70% reduction in the need for ICU admission respectively when compared to patients without vaccination. both of them were statistically significant($p<0.05$). RTPCR positive patients with at least one dose of Covid 19 vaccine and full vaccinated RTPCR positive patients had a 60% and 90% reduction in the need for oxygen therapy respectively when compared to patients with RT PCR negative and it was statistically significant ($p<0.05$). Both were statistically significant($p<0.05$). (Table 4)

The proportion of patients who died:

Those aged more than 59 years (1.6 times) and patients with co-morbidity (1.2 times) had more odds of dying and it was statistically significant($p<0.05$) (Table 2).

SARI patients with at least one dose of Covid 19 vaccine and fully vaccinated SARI patients had a 20% and 85% reduction in the need for ICU admission respectively when compared to patients without vaccination. however, both were not statistically significant($p>0.05$). RTPCR positive patients with at least one dose of Covid 19 vaccine and full vaccinated RTPCR positive patients had a 20% and 80% reduction in the need for oxygen therapy respectively when compared to patients with RT PCR negative and it was statistically significant ($p<0.05$ however, both of them were not statistically significant($p>0.05$). (Table 4).

Discussion:

We did this retrospective cross-sectional study among the patients admitted in the Covid 19 wards of a tertiary care hospital during the second wave of the Covid 19 pandemic. In our study, only 3.8% of SARI patients and 4% of the RTPCR positive patients were vaccinated which is comparable to the district data as well as the state vaccine coverage(10). There is a possibility that vaccination could have reduced the need for hospitalization which needs to be explored.

Our study couldn't find any protective effect of vaccination against new COVID 19 infections. Type of vaccine nor number of doses of vaccines has any effect on the incidence of infection. Victor et al had

documented that the protective effect of covid vaccination in preventing infection, hospitalization, need for oxygen and ICU admission were 65%, 77%, 92% and 94% respectively(13). VIN-WIN cohort study conducted among 1.59 million health care workers and frontline workers of Indian Armed Forces showed a 93% reduction in breakthrough infection following Covishield vaccination(14). Ella et al(6), Voysey et al(5) had also documented the protective effect of the vaccine in preventing infection. But we couldn't find any protective effect of the vaccine in preventing the infection following vaccination. Less number of vaccinated patients and lesser hospitalizations among them in our study might be one of the reasons. The difference in health-seeking behaviour among the vaccinated and non-vaccinated patients could have resulted in different rates of hospital admission also (8).

The proportion of SARI patients and RT PCR positive patients who required oxygen support, ICU admission and died reported by our study was significantly higher than the first wave studies and also other studies done during the second wave in India. Our study had found that 80% of patients with SARI and 79 % of the RT PCR positive patients required oxygen. 65% of the SARI patients and 63% of the RT PCR positive patients had a severe infection and needed ICU admission. 23 % of the SARI patients and 29.7% of RTPCR positive patients had died during the hospital stay. Kumar G et al had reported that 50 % of patients needed oxygen support and high mortality during the second wave which is in line with our findings. This is in contrast to the finding that only 5-15% percentage of the patients had the severe disease as reported by the first wave study findings (15–20). More transmission and more virulence were noticed in the second wave which suggests that this could be due to different virus strains (21). Another important reason for the high proportion of patients with severe disease could be the hospital admission policy.

Only 31 % of fully vaccinated Covid 19 positive patients had oxygen requirement (90% less risk of requiring oxygen during admission) and 15% of the fully vaccinated patients had needed ICU admission (90 % less risk of ICU admission) as compared to non-vaccinated people (78%, 62% respectively) and it was significant. Only 7.7% (n=1) of the fully vaccinated covid 19 positive patients had died; 80 % less risk of

death as compared to non-vaccinated people (30%) and however it was not significant. More number of samples are needed to conclude further.

The protective effect shown by the vaccines in preventing a severe form of the disease found in our study is comparable with other studies. However, the Protective effect shown by the vaccines in preventing death was low as compared to other studies. Lesser number of deaths reported among the vaccinated group might be the reason. Victor et al have reported a high protective effect of vaccination in preventing the need for oxygen (92%) and ICU admission (94%) among health care workers in India(13). Jaiswal et al had documented 95 % effectiveness in preventing death among fully vaccinated people(High-risk group)(24). Christie et al have documented that improved vaccination coverage has reduced hospital admissions, the need for oxygen supplementation and ICU admission in the United States of America(25). After vaccinating more than 70% of the population with two doses of BNT162b2, Israel had significantly reduced hospitalization and ICU admission(26). Bernel et al have reported the real-world effectiveness of oxford Astra Zeneca in preventing ICU admissions as 73% in England (27). Pooled analysis of randomized control trials on ChAdOx1 nCoV-19 vaccines by Voysey et al showed that two standard doses had given 66.7% protection against hospitalization and symptomatic infections(28). The efficacy of the covishield vaccine against symptomatic infections was found to be 76% after the first dose. If the interval between the first and second dose was extended to 12 weeks or more the efficacy rose to 91.6%(5). Not many studies are available in India in this category to make more comparisons. Our study findings are comparable to other studies however the protective effect documented by them was higher than ours. A possible reason would be the smaller number of vaccinated (n=94) and fully vaccinated patients(n=21) in our study. The inclusion of a greater number of vaccinated people may give more evidence. There is a paucity of studies in this field and more samples are needed to conclude further.

Limitation:

The proportion of vaccinated and fully vaccinated patients were low in our study. Explicit research with more sample size and negative case-control study is quintessential to corroborate the findings.

Conclusion:

Vaccination didn't protect against new SARS Cov-2 infection. The proportion of SARI patients and RT PCR positive patients who required oxygen support, ICU admission and died was significantly high. Covid vaccination significantly reduced the severity of illness among SARI patients and even more reduction in risk was documented among the RT PCR positive patients. The protective effect shown by the vaccines in preventing a severe form of SARS Cov-2 infection among fully vaccinated patients was 90%. Vaccination coverage should be increased urgently to halt the impending wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Financial support & Sponsorship: Nil

Conflicts of interest: Nil

Tables:

Table 1: Distribution of Baseline variables and study variables(n=3679)		
Sex wise distribution		
Sex	Frequency	Percentage
Male	2206	60%
Female	1473	40%
Age wise distribution		
Age group	Frequency	Percentage
<20 years	19	0.52%
21-30 years	145	3.94%
31- 40 years	357	9.70%
41-50 years	628	17.07%
51-60 years	962	26.15%
61-70 years	999	27.15%
71-80 years	440	11.96%
81-90 years	123	3.34%
91-100 years	6	0.16%
Mean age: 56.9 years, Median: 59 years; Standard deviation: 14.2, Range 13 years to 94 years		
Proportion of symptomatic patients		
Yes	3486	94.80%
No	193	5.20%
Proportion of patients with co- morbid conditions		
Yes	1953	53%
No	1726	47%
Proportion of patients RT- PCR positive		
Yes	1616	44%
No	2063	56%
Proportion of patients vaccinated (n=2480)		
Yes	94	3.80%
No	2386	96.20%
Clinical Category wise distribution		
Mild	713	19.40%
Moderate	578	15.70%
Severe	2388	64.90%
Proportion of patients with SARI needed oxygen		
Yes	2966	80.60%
No	713	19.40%
Proportion of patients with SARI needed ICU admission		
Yes	2388	64.90%
No	1291	35.10%
Proportion of patients died		
Yes	862	23.40%
No	2817	76.60%

Table 2: Comparison of baseline variables and outcome										
Baseline variables VS Outcome among SARI patients (n=3679)										
		Patients requiring Oxygen			Patients requiring ICU admission			Death		
Variables		Yes (n=2966)	No (n=713)	Odd's ratio (95%CI)	Yes (n=2388)	No (n=1291)	Odd's ratio (95%CI)	Yes (n=823)	No (n=2670)	Odd's ratio (95%CI)
Sex	Female	1201 (81.5%)	272 (18.5%)	1.1 (0.9 to 1.3)	992 (67.3%)	481 (32.7%)	1.2*	317 (22.6%)	1087 (77.4%)	0.9 (0.8 to 1.1)
	Male	1765 (80%)	441 (20%)		1396 (63.2%)	810 (36.8%)	(1.1 to 1.4)	506 (24.3%)	1583 (75.7%)	
Age >59 years	Yes	1564 (84.8%)	280 (15.2%)	1.7* (1.5 to 2)	1278 (69.3%)	566 (30.7%)	1.5*	498 (27%)	1346 (73%)	1.5* (1.3 to 1.9)
	No	1402 (76.4%)	433 (23.6%)		1110 (60.5%)	725 (39.5%)	(1.3 to 1.7)	364 (19.8%)	1471 (80.2%)	
Presence of co-morbid conditions	No	1448 (83.9%)	278 (16.1%)	1.5* (1.3 to 1.8)	1189 (69.3%)	537 (30.8%)	1.4*	336 (19.5%)	1390 (80.5%)	0.7* (0.6 to 0.7)
	Yes	1518 (77.7%)	435 (22.3%)		1199 (61.4%)	754 (38.6%)	(1.2 to 1.6)	526 (26.9%)	1427 (73.1%)	
Baseline variables Vs Outcome among RT PCR positive patients (n=1616)										
		Patients requiring Oxygen			Patients requiring ICU admission			Death		
Variables		Yes (n=1270)	No (n=346)	Odd's ratio (95%CI)	Yes (n=1017)	No (n=599)	Odd's ratio (95%CI)	Yes (n=477)	No (n=2679)	Odd's ratio (95%CI)
Sex	Female	527 (79.6%)	135 (20.4%)	1.1 (0.9 to 1.4)	440 (66.5%)	222 (33.5%)	1.3* (1 to 1.6)	192 (29%)	470 (71%)	1 (0.8 to 1.2)
	Male	743 (77.9%)	211 (22.1%)		577 (60.5%)	377 (39.5%)		285 (29.9%)	669 (70.1%)	
Age >59 years	Yes	701 (83.3%)	141 (16.7%)	1.8* (1.4 to 2.3)	557 (66.2%)	285 (33.8%)	1.3* (1 to 1.6)	284 (33.7%)	558 (66.3%)	1.5* (1.2 to 1.9)
	No	569 (73.5%)	205 (26.5%)		460 (59.4%)	314 (40.6%)		193 (25%)	581 (75%)	
Presence of co-morbid conditions	No	610 (81.3%)	140 (18.7%)	1.4* (1.1 to 1.7)	348 (40.2%)	518 (59.8%)	1.3* (1 to 1.6)	179 (23.9%)	571 (76.1%)	0.6*(1.6)
	Yes	660 (76.2%)	206 (23.8%)		251 (33.5%)	499 (66.5%)		298 (34.4%)	568 (65.6%)	(0.5 to 0.7)

*p value <0.05

Table 3: Effectiveness of Covid 19 vaccine (n=2480)				
Occurrence of New infection				
	Category	RT PCR Positive	RT PCR Negative	Odd's ratio(95%CI)
		(n=1394)	(n=1086)	
Vaccinated	Yes	56(59.6%)	38(40.4%)	1.2 (0.8 to 1.8)
	No	1338(56%)	1048(44%)	
Type of vaccine	Covishield	40(55.6%)	32(44.4%)	0.5 (0.2 to 1.4)
	Covaxin	16(72.7%)	6(27.3%)	
Number of doses	0 dose (n=2386)	1338(56%)	1048(44%)	1
	1 dose (n=73)	43(58.9%)	30(41.1%)	1.1
	2 doses (n=21)	13(61.9%)	8(38.1%)	1.3

*p value <0.05

Table 4: Comparison of Vaccination and Outcome										
Vaccination Vs Outcome among SARI patients (n=2480)										
		Patients requiring Oxygen			Patients requiring ICU admission			Death		
Variables		Yes (n=1911)	No (n=569)	Odd's ratio (95%CI)	Yes (n=1411)	No (n=940)	Odd's ratio (95%CI)	Yes (n=579)	No (n=1772)	Odd's ratio (95%CI)
Vaccinated	Yes	54 (57.5%)	40 (42.5%)	0.38* (0.26 to 0.6)	41 (43.6%)	53 (56.4%)	0.5* (0.3 to 0.8)	20 (21.3%)	74 (78.7%)	0.8 (0.5 to 1.3)
	No	1857 (77.8%)	529 (22.2%)		1432 (60%)	954 (40%)		599 (25%)	1787 (75%)	
Type of vaccine	Covaxin	7 (31.8%)	15 (68.2%)	0.25 (0.08 to 0.7)	5 (22.7%)	17 (77.3%)	0.3* (0.1 to 0.95)	4 (18.2%)	18 (81.8%)	0.8 (0.2 to 2.8)
	Covishield	47 (65.3%)	25 (34.7%)		36 (50%)	36 (50%)		16 (22.2%)	56 (77.8%)	
Number of doses	0 dose	1857 (77.8%)	529 (22.2%)	1	1432 (60%)	954 (40%)	1	599 (25%)	1787 (75%)	1
	1 dose	46 (63%)	27 (37%)	0.5	35 (48%)	38 (52%)	0.6	19 (26%)	54 (74%)	1.1
	2 doses	8 (38.1%)	13 (61.9%)	0.2*	6 (28.6%)	15 (71.4%)	0.3*	1 (4.8%)	20 (95.2%)	0.15
Vaccination Vs Outcome among RT PCR positive patients(n=1394)										
		Patients requiring Oxygen			Patients requiring ICU admission			Death		
Variables		Yes (n=1911)	No (n=569)	Odd's ratio (95%CI)	Yes (n=1411)	No (n=940)	Odd's ratio (95%CI)	Yes (n=579)	No (n=1772)	Odd's ratio (95%CI)
Vaccinated	Yes	27 (48.2%)	29 (51.8%)	0.25* (0.15 to 0.44)	22 (39.3%)	34 (60.7%)	0.4* (0.2 to 0.6)	14 (25%)	42 (75%)	0.8 (0.4 to 1.4)
	No	1047 (78.3%)	291 (21.7%)		826 (61.7%)	512 (31.3%)		401 (30%)	937 (70%)	
Type of vaccine	Covaxin	4(25%)	12 (75%)	0.25* (0.08 to 0.9)	3 (18.8%)	13 (81.2%)	0.26 (0.06 to 1.03)	3 (18.8%)	13 (81.2%)	0.6 (0.14 to 2.6)
	Covishield	23(57.5 %)	17(42.5%)		19 (47.5%)	21 (52.5%)		11 (27.5%)	29 (72.5%)	
Number of doses	0 dose	1047 (78.3%)	291 (21.7%)	1	826 (61.7%)	512 (31.35)	1	401(30%)	937 (70%)	1
	1 dose	23 (53.5%)	20 (46.5%)	0.3	20 (46.5%)	23 (53.5%)	0.5	13 (30%)	30 (70%)	1.2
	2 doses	4 (30.8%)	9 (69.2%)	0.1*	2 (15.4%)	11 (84.6%)	0.1*	1 (7.7%)	12 (92.3%)	0.2

*p value <0.05

BIBLIOGRAPHY:

1. Coronavirus [Internet]. [cited 2021 Aug 9]. Available from: https://www.who.int/westernpacific/health-topics/coronavirus

2. Data at WHO [Internet]. [cited 2021 Aug 9]. Available from: https://www.who.int/data

3. Kofman A, Kantor R, Adashi EY. Potential COVID-19 Endgame Scenarios: Eradication, Elimination, Cohabitation, or Conflagration? JAMA [Internet]. 2021 Jul 8 [cited 2021 Jul 10]; Available from: https://jamanetwork.com/journals/jama/fullarticle/2781945

4. Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine, ICMR, JAN,2021 [Internet]. [cited 2021 Jul 7]. Available from: https://www.icmr.gov.in/pdf/press_realease_files/HFW_DCGI_energency_use_authorisation_03012021_2.pdf

5. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single Dose Administration, And the Influence of The Timing of The Booster Dose on Immunogenicity and Efficacy of ChAdOx1 to-19 (AZD1222) Vaccine [Internet]. Rochester, NY: Social Science Research Network; 2021 Feb [cited 2021 Jul 7]. Report No.: ID 3777268. Available from: https://papers.ssrn.com/abstract=3777268

6. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 Jul 1;21(7):950–61.

7. Revised Guidelines for implementation of National COVID Vaccination Program, MOHFW, Government of India, June 2021 [Internet]. [cited 2021 Jun 16]. Available from: https://www.mohfw.gov.in/pdf/RevisedVaccinationGuidelines.pdf

8. Evaluation of COVID-19 vaccine effectiveness, Interim guidance, World Health Organization,17 March 2021.

9. Ten health issues WHO will tackle this year [Internet]. [cited 2021 Aug 6]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

10. Coronavirus in India: Latest Map and Case Count [Internet]. [cited 2021 Aug 6]. Available from: https://www.covid19india.org

11. UpdatedDetailedClinicalManagementProtocolforCOVID19 for adults ,Ministry of health and family welfare,Government of India, MAY 2021pdf [Internet]. [cited 2021 Jul 5]. Available from: https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf

12. COVID-19 Breakthrough Case Investigations and Reporting | CDC [Internet]. 2021 [cited 2021 Jul 7]. Available from: https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html

13. Victor PJ, Mathews KP, Paul H, Murugesan M, Mammen JJ. Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the pandemic in India. Mayo Clin Proc. 2021 Jun;S0025619621004705.

14. Ghosh S, Shankar S, Chatterjee K, Chatterjee K, Yadav AK, Pandya K, et al. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of Indian Armed Forces: Interim results of VIN-WIN cohort study. Med J Armed Forces India. 2021 Jul;77:S264–70.

15. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 28;323(16):1574–81.

16. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020 01;3(6):e2012270.

17. Mohan A, Tiwari P, Bhatnagar S, Patel A, Maurya A, Dar L, et al. Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. Indian J Med Res. 2020 Aug;152(1 & 2):61–9.

18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054–62.

19. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239.

20. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021 Mar;93(3):1449–58.

21. Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Jul 15]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants

22. Tandon VR, Meeta M. COVID-19 pandemic – Impact on elderly and is there a gender bias? J -Life Health. 2020 Jul 1;11(3):117.

23. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Ageing. 2020 May 29;12(10):9959–81.

24. Jaiswal A, Subbaraj V, Vivian Thangaraj J, Murhekar ManojV, Muliyil J. COVID-19 vaccine effectiveness in preventing deaths among high-risk groups in Tamil Nadu, India. Indian J Med Res. 2021;0(0):0.

25. Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;858–64.

26. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021 May 15;397(10287):1819–29.

27. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: a test-negative case-control study. BMJ. 2021 May 13;373:n1088.

28. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet Lond Engl. 2021 Mar 6;397(10277):881–91.

Table 3: Effectiveness of Covid 19 vaccine (n=2480)				
Occurrence of New infection				
	Category	RT PCR Positive	RT PCR Negative	Odd's ratio(95%CI)
		(n=1394)	(n=1086)	
Vaccinated	Yes	56(59.6%)	38(40.4%)	1.2 (0.8 to 1.8)
	No	1338(56%)	1048(44%)	
Type of vaccine	Covishield	40(55.6%)	32(44.4%)	0.5 (0.2 to 1.4)
	Covaxin	16(72.7%)	6(27.3%)	
Number of doses	0 dose (n=2386)	1338(56%)	1048(44%)	1
	1 dose (n=73)	43(58.9%)	30(41.1%)	1.1
	2 doses (n=21)	13(61.9%)	8(38.1%)	1.3